ASH 2024

Questions discussed in this category

Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?

3 Answers available

Papers discussed in this category

The New England journal of medicine, 2024 Dec 09

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Blood advances, 2023 Nov 14

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Related Topics